A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Tesamorelin is a 44-amino-acid growth hormone-releasing hormone (GHRH) analog — the strongest and longest-acting compound in its class, producing a bigger, more sustained growth hormone response than Sermorelin. It’s also the only FDA-approved growth hormone secretagogue currently in clinical use, approved as EGRIFTA (2010) and, in an updated formulation, EGRIFTA WR (2025) — specifically for reducing excess abdominal (visceral) fat in patients with HIV-associated lipodystrophy.
Visceral fat isn’t just extra padding — it behaves like an active inflammatory organ, producing substances that drive insulin resistance and cardiovascular risk. Growth hormone preferentially targets this type of fat for breakdown, which is why Tesamorelin’s stronger GH stimulus produces a disproportionate reduction specifically in visceral fat compared to fat just under the skin. In its approved Phase 3 trials, it produced roughly a 19.6% reduction in visceral adipose tissue compared to placebo.
Worth being clear-eyed about: Tesamorelin’s visceral-fat-reducing effect isn’t unique to it specifically — any growth-hormone-axis peptide that raises GH will tend to reduce visceral fat, since that’s how growth hormone itself behaves in the body. What makes Tesamorelin different is that it’s the one compound in this category with FDA approval and the strongest clinical evidence behind it. Outside of its approved HIV-lipodystrophy indication, it’s sometimes used off-label as part of an individualized metabolic or body-composition protocol, with fasting glucose and IGF-1 monitored along the way since it produces a stronger GH stimulus than Sermorelin or CJC-1295.
Because Tesamorelin drives a stronger fat-burning (lipolytic) demand than gentler GH-axis peptides, the nutrient cofactors that support fat metabolism matter more here, not less. Our clinical reference specifically flags B1, B2, B5, and acetyl-L-carnitine as priority cofactors for the fat-oxidation pathway Tesamorelin activates, alongside the general GH-axis needs of zinc, magnesium, and adequate dietary protein.
Tesamorelin is FDA-approved under the brand name EGRIFTA (and the updated EGRIFTA WR formulation) specifically for HIV-associated lipodystrophy. Use for any other purpose, including general metabolic or longevity goals, is considered off-label. Active or suspected malignancy is an explicit contraindication on the FDA label, and because it produces a stronger GH stimulus than gentler options, fasting glucose and HbA1c monitoring is especially important. Visceral fat reduction typically returns toward baseline within 6–12 months of stopping, which is worth factoring into any long-term plan.
Tesamorelin’s FDA-approved indication is specifically for reducing excess visceral (abdominal) fat in patients with HIV-associated lipodystrophy. In the clinical trials supporting this approval, researchers observed a measurable reduction in visceral adipose tissue in that specific patient population — this is the basis for Tesamorelin’s approved use. Use for other purposes, in patients without this diagnosis, is considered off-label, and individual outcomes vary based on many factors; whether it’s appropriate for you is something our providers determine individually.
Tesamorelin works by stimulating the body’s own growth hormone release, and growth hormone is well established in endocrine physiology to promote lipolysis (the breakdown of stored fat for use as fuel). This physiological mechanism, combined with Tesamorelin’s approved visceral-fat-reduction indication, is why it comes up in conversations about body composition. This describes the underlying biology and the compound’s approved indication — it is not a guarantee of any specific outcome for an individual patient outside that approved use.
Learn more about the pathway Tesamorelin works within: Growth Hormone & IGF-1. Compare with Sermorelin and Ipamorelin, or see Hexarelin.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
